Literature DB >> 27735143

Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India.

Vandana Pradhan1, Pallavi Pandit2, Anjali Rajadhyaksha3, Manisha Patwardhan4, Prathamesh Surve5, Pradnya Kamble6, Maxime Lecerf7, Jagadeesh Bayry8, Srinivas Kaveri9, K Ghosh10, Milind Y Nadkar11.   

Abstract

OBJECTIVE: To identify the hematological manifestations and its association with serum ferritin levels in SLE patients from Western India.
METHODS: Ninety clinically diagnosed SLE patients fulfilling ACR criteria were included. Disease activity was assessed at the time of evaluation using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Sera were tested for serum ferritin levels by ELISA (Calbiotech, USA). Autoantibodies such as ANA, anti-dsDNA by indirect immunofluorescence test (IFA- Bio-Rad, USA) and anti-cardiolipin antibodies (ACA) to IgG and IgM isotypes and Anti-β2 GP antibodies to IgG and IgM isotypes were detected by ELISA using commercially available kits (Euroimmun, Lubeck, Germany).
RESULTS: Out of 90 SLE patients studied, 41 patients (45.6%) showed hematological abnormalities, where anemia (82.9%), leucopenia (26.8%), autoimmune hemolytic anemia (AIHA) (14.6%) and idiopathic thrombocytopenic purpura (ITP) were noted in (34.1%) patients. Mean±SD serum ferritin levels among SLE patients were 270.2±266.0 ng/ml as compared to 29.0±15.8 ng/ml healthy normal controls (p<0.0001). A positive correlation between serum ferritin levels and SLEDAI scores (r= 0.2640, p=0.0124) and anti-dsDNA positivity was noted (r=0.32, p<0.0001). Serum ferritin levels were negatively correlated with hemoglobin levels (r=-0.5964, p=0.0001), WBC count (r=-0.1705, p=0.2316), platelet count ((r=-0.1701, P=0.2375), C3 levels (r=-0.4417, p=0.0034) and C4 levels (r=-0.0363, p=0.8215).
CONCLUSIONS: Serum ferritin is an excellent marker of SLE which can be used for an evaluation of disease activity particularly in active stage of the disease mainly in patients having hematological and renal manifestations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27735143

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  6 in total

1.  Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity.

Authors:  Lin Qi; Jingyi Xu; Chunshu Yang; Xiaoyu Hou; Pingting Yang
Journal:  Clin Rheumatol       Date:  2020-06-16       Impact factor: 2.980

2.  Hepcidin and Ferritin: Important Mediators in Inflammation Associated Anemia in Systemic Lupus Erythematosus Patients.

Authors:  Neeraja Kunireddy; Rachel Jacob; Siraj Ahmed Khan; B Yadagiri; K S S Sai Baba; I Rajendra Vara Prasad; Iyyapu Krishna Mohan
Journal:  Indian J Clin Biochem       Date:  2017-10-28

3.  Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium.

Authors:  Samar A Soliman; Anam Haque; Sherene Mason; Larry A Greenbaum; M John Hicks; Chandra Mohan; Scott E Wenderfer
Journal:  Lupus       Date:  2021-05-14       Impact factor: 2.911

Review 4.  Use of acute phase proteins for the clinical assessment and management of canine leishmaniosis: general recommendations.

Authors:  J J Ceron; L Pardo-Marin; M Caldin; T Furlanello; L Solano-Gallego; F Tecles; L Bernal; G Baneth; S Martinez-Subiela
Journal:  BMC Vet Res       Date:  2018-06-20       Impact factor: 2.741

5.  The clinical implications of serum ferritin in Kawasaki disease: a helpful biomarker for evaluating therapeutic responsiveness, coronary artery involvement and the tendency of macrophage activation syndrome.

Authors:  Zhen Qiu; Hui Hui Liu; Guo Zhen Fan; Wei Xia Chen; Peng Hu
Journal:  Arch Med Sci       Date:  2021-12-08       Impact factor: 3.318

6.  Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria.

Authors:  Eileen S Marks; Mathilde L Bonnemaison; Susan K Brusnahan; Wenting Zhang; Wei Fan; Jered C Garrison; Erika I Boesen
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.